N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxy-5-(2-(1-methyl-1H-indol-3-yl)pyrimidin-4-ylamino)phenyl)acrylamide

ID: ALA4206501

Chembl Id: CHEMBL4206501

PubChem CID: 145977147

Max Phase: Preclinical

Molecular Formula: C28H33N7O2

Molecular Weight: 499.62

Molecule Type: Small molecule

Associated Items:

Names and Identifiers

Canonical SMILES:  C=CC(=O)Nc1cc(Nc2ccnc(-c3cn(C)c4ccccc34)n2)c(OC)cc1N(C)CCN(C)C

Standard InChI:  InChI=1S/C28H33N7O2/c1-7-27(36)31-21-16-22(25(37-6)17-24(21)34(4)15-14-33(2)3)30-26-12-13-29-28(32-26)20-18-35(5)23-11-9-8-10-19(20)23/h7-13,16-18H,1,14-15H2,2-6H3,(H,31,36)(H,29,30,32)

Standard InChI Key:  BVNDWJSTWPXVCD-UHFFFAOYSA-N

Alternative Forms

  1. Parent:

    ALA4206501

    ---

Associated Targets(Human)

EGFR Tclin Epidermal growth factor receptor erbB1 (33727 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
ERBB3 Tclin Receptor tyrosine-protein kinase erbB-3 (297 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Small moleculeTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Calculated Properties

Molecular Weight: 499.62Molecular Weight (Monoisotopic): 499.2696AlogP: 4.51#Rotatable Bonds: 10
Polar Surface Area: 87.55Molecular Species: BASEHBA: 8HBD: 2
#RO5 Violations: 0HBA (Lipinski): 9HBD (Lipinski): 2#RO5 Violations (Lipinski): 0
CX Acidic pKa: CX Basic pKa: 8.87CX LogP: 4.75CX LogD: 3.26
Aromatic Rings: 4Heavy Atoms: 37QED Weighted: 0.31Np Likeness Score: -1.10

References

1. Planken S, Behenna DC, Nair SK, Johnson TO, Nagata A, Almaden C, Bailey S, Ballard TE, Bernier L, Cheng H, Cho-Schultz S, Dalvie D, Deal JG, Dinh DM, Edwards MP, Ferre RA, Gajiwala KS, Hemkens M, Kania RS, Kath JC, Matthews J, Murray BW, Niessen S, Orr ST, Pairish M, Sach NW, Shen H, Shi M, Solowiej J, Tran K, Tseng E, Vicini P, Wang Y, Weinrich SL, Zhou R, Zientek M, Liu L, Luo Y, Xin S, Zhang C, Lafontaine J..  (2017)  Discovery of N-((3R,4R)-4-Fluoro-1-(6-((3-methoxy-1-methyl-1H-pyrazol-4-yl)amino)-9-methyl-9H-purin-2-yl)pyrrolidine-3-yl)acrylamide (PF-06747775) through Structure-Based Drug Design: A High Affinity Irreversible Inhibitor Targeting Oncogenic EGFR Mutants with Selectivity over Wild-Type EGFR.,  60  (7): [PMID:28287730] [10.1021/acs.jmedchem.6b01894]

Source